RXDX - Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases

• Prometheus displays positive phase 1 safety data with PRA023. Drug also shows target engagement with mode of action in healthy volunteers.
• Based on the phase 1 data, biotech has added a 3rd indication for PRA023, which is Systemic Sclerosis-Associated Lung disease. Phase 1 study to start Q1 of 2022.
• Phase 2 results using PRA023 for both Ulcerative Colitis and Crohn's Disease are expected to be released in Q4 of 2022.
• An IND submission using another monoclonal antibody from the TNF superfamily, known as PR600, is expected in Q3 of 2022.

For further details see: